This is a working overview of Angiotensin IV analog, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-04-12 and is reviewed periodically as new material appears.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
| Property | Value | Notes |
|---|---|---|
| Chemical name | N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Common full name in research literature. |
| Class | Synthetic peptide | Modified angiotensin IV analog. |
| Related compound | Angiotensin IV | Parent peptide fragment. |
| Proposed target | HGF/c-Met pathway | Described as an HGF mimetic; not fully confirmed. |
| Development status | Preclinical research | No widely approved clinical use. |
Purity and identity are usually assessed with reverse-phase high-performance liquid chromatography (RP-HPLC) and mass spectrometry. RP-HPLC separates components by hydrophobicity and can estimate peptide purity. Mass spectrometry confirms molecular mass and helps detect truncations or modifications. Some laboratories also use amino acid analysis or nuclear magnetic resonance for structural verification. A certificate of analysis from a supplier may list these results, but independent verification is often recommended for critical work.
Regulatory status varies by country, and dihexa is not widely approved as a medicine. In many jurisdictions it is treated as a research chemical, which limits its legal sale, possession, and human use. Products marketed online may lack verified purity or identity, and labels can be inaccurate. Researchers typically source material from suppliers that provide analytical documentation and follow institutional safety rules. Open questions remain about long-term stability, metabolite formation, and human pharmacokinetics.
The proposed mechanism of dihexa centers on activation of the hepatocyte growth factor receptor, also called c-Met. Some studies suggest it acts as a mimetic of hepatocyte growth factor, promoting signaling pathways involved in synapse formation. Other work has explored interactions with angiotensin IV pathways, but the exact binding targets remain uncertain. Laboratory findings come mainly from cell cultures and animal models. Whether these mechanisms operate similarly in humans is an open question. Researchers have not established a single, universally accepted mechanism of action.
Identity and purity of dihexa samples are typically assessed with high-performance liquid chromatography and mass spectrometry. These methods can confirm molecular mass and estimate the presence of impurities. However, a certificate of analysis from a supplier is not a guarantee of independent testing. Researchers often require in-house verification before using a peptide in experiments. For solid samples, appearance, solubility, and chromatographic profile provide additional checks. Nuclear magnetic resonance may be used for structural confirmation when available.
Dihexa is commonly handled as a lyophilized powder in laboratory settings. Storage at -20 °C in a desiccated, light-protected container is typical for peptides. Repeated freeze-thaw cycles can degrade the material, so aliquoting is often recommended. Aqueous solutions may be less stable than organic stocks and should be prepared fresh when possible. Personnel should follow institutional safety procedures and avoid uncontrolled exposure. Because human effects are not well characterized, handling precautions are prudent.
Glycogen is a molecular polymer of glucose (a polysaccharide) used to store energy, and is important for maintaining glucose homeostasis in the blood, as well as for providing energy for skeletal muscle and cardiac muscle contraction. Molecules of glucose are linked into linear chains by α-1,4-glycosidic bonds. Additionally, branches of glucose are formed off of the chain by α-1,6-glycosidic bonds. 2 molecules of glucose are joined into an α-1,4-glycosidic bonds by an enzyme known as glycogen synthase. This bond may be broken by glycogen phosphorylase when the body wishes to break down glycogen into glucose for energy. Glycogen branching enzyme is responsible for the required α-1,6-glycosidic bonds needed to start a branch off of these linear chains. Any disruption to this system results in a glycogen storage disease. There are currently 2 subcategories of glycogen storage diseases in horses: Type 1 polysaccharide storage myopathy, glycogen branching enzyme deficiency, and Type 2 polysaccharide storage myopathy.
1993/788) Legal Aid in Criminal and Care Proceedings (General) (Amendment) Regulations 1993 (S.I. 1993/789) Legal Advice and Assistance (Amendment) Regulations 1993 (S.I. 1993/790) Measuring Instruments (EEC Requirements) (Fees) Regulations 1993 (S.I. 1993/798) Public Lending Right (Increase of Limit) Order 1993 (S.I. 1993/799)
=== Managing warfarin therapy === Warfarin is an anticoagulant drug. It functions by inhibiting an enzyme that is responsible for recycling vitamin K to a functional state. As a consequence, proteins that should be modified by vitamin K are not, including proteins essential to blood clotting, and are thus not functional. The purpose of the drug is to reduce risk of inappropriate blood clotting, which can have serious, potentially fatal consequences. The proper anticoagulant action of warfarin is a function of vitamin K intake and drug dose. Due to differing absorption of the drug and amounts of vitamin K in the diet, dosing must be monitored and customized for each patient. Some foods are so high in vitamin K1 that medical advice is to avoid those (examples: collard greens, spinach, turnip greens) entirely, and for foods with a modestly high vitamin content, keep consumption as consistent as possible, so that the combination of vitamin intake and warfarin keep the anti-clotting activity in the therapeutic range. Vitamin K is a treatment for bleeding events caused by overdose of the drug. The vitamin can be administered by mouth, intravenously or subcutaneously. Oral vitamin K is used in situations when a person's International normalized ratio is greater than 10 but there is no active bleeding. The newer anticoagulants apixaban, dabigatran and rivaroxaban are not vitamin K antagonists.
Sources: en.wikipedia.org
=== Amphetamines === Amphetamines are a chemical class of stimulants, entactogens, hallucinogens, and other drugs. They feature a phenethylamine core with a methyl group attached to the alpha carbon resulting in amphetamine, along with additional substitutions.
coli for animals and humans Kentucky Bioprocessing took over Large Scale Biology's facilities in Owensboro, Kentucky, and offers contract biomanufacturing services in tobacco plants, grown in greenhouses or in open fields. Medicago Inc. – Pre-clinical trials of Influenza vaccine made in transiently infected Nicotiana benthamiana (relative of tobacco) plants in greenhouses. Medicago grew virus-like particles in the Australian weed Nicotiana benthamiana, for development of a candidate vaccine against the COVID-19 virus, initiating a Phase I clinical trial in July 2020. PharmaPraxis – Developing biosimilars in collaboration with PlantForm (see below) and Fraunhofer. Pharming – C1 inhibitor, human collagen 1, fibrinogen (with American Red Cross), and lactoferrin in cow milk The intellectual property behind the fibrinogen project was acquired from PPL Therapeutics when PPL went bankrupt in 2004. Phyton Biotech uses plant cell culture systems to manufacture active pharmaceutical ingredients based on taxanes, including paclitaxel and docetaxel Planet Biotechnology – antibodies against Streptococcus mutans, antibodies against doxorubicin, and ICAM 1 receptor in tobacco PlantForm Corporation – biosimilar trastuzumab in tobacco – It is developing biosimilars in collaboration with PharmaPraxis (see above) and Fraunhofer. ProdiGene – was developing several proteins, including aprotinin, trypsin and a veterinary TGE vaccine in corn. Was in process of launching trypsin product in 2002 when later that year its field test crops contaminated conventional crops.
== Named after Dyson == Dyson conjecture Dyson equation Dyson numbers Dyson operator Dyson series Dyson sphere Dyson tree Dyson's crank Dyson's eternal intelligence Dyson's transform Dyson–Maleev spin wave theory Schwinger–Dyson equation Thue–Siegel–Dyson–Roth theorem Feynman diagram, also known as Dyson graphs Wigner–Yamase–Dyson conjecture Gordon Freeman, a fictional character named after Dyson
== After WWII == In 1968, Victor Saxl died and Eva moved to Santiago, Chile, to live with her brother, her only living relative. There she would remain vigilant as an advocate for people with Type 1 diabetes. Eva Saxl died in 2002 in Santiago. The Saxls' story was dramatized by the 1956–1958 CBS television show Telephone Time in an episode titled "Time Bomb".
Sources: en.wikipedia.org
== External links == "Melanocortin Receptors". IUPHAR Database of Receptors and Ion Channels. International Union of Basic and Clinical Pharmacology. Melanocortin+Receptors at the U.S. National Library of Medicine Medical Subject Headings (MeSH) Calculated spatial position of melanocortin-4 receptor in the lipid bilayer, inactive state with antagonist and active state with agonist
There is a clear relationship between known hydrocarbon discoveries at great depth in the Gulf slope and chemosynthetic communities, hydrocarbon seepage, and authigenic minerals including carbonates at the seafloor. While the hydrocarbon reservoirs are broad areas several kilometers beneath the Gulf, chemosynthetic communities occur in isolated areas with thin veneers of sediment only a few meters thick. The northern Gulf of Mexico slope includes a stratigraphic section more than 10 km (6.2 mi) thick and has been profoundly influenced by salt movement. Mesozoic source rocks from Upper Jurassic to Upper Cretaceous generate oil in most of the Gulf slope fields. Migration conduits supply fresh hydrocarbon materials through a vertical scale of 6–8 km (3.7–5.0 mi) toward the surface. The surface expressions of hydrocarbon migration are called seeps. Geological evidence demonstrates that hydrocarbon and brine seepage persists in spatially discrete areas for thousands of years. The time scale for oil and gas migration from source systems is on the scale of millions of years (Sassen, 1997). Seepage from hydrocarbon sources through faults towards the surface tends to be diffused through the overlying sediment, carbonate outcroppings, and hydrate deposits, so the corresponding hydrocarbon seep communities tend to be larger (a few hundred meters wide) than chemosynthetic communities found around the hydrothermal vents of the Eastern Pacific (MacDonald, 1992). There are large differences in the concentrations of hydrocarbons at seep sites.
=== General uses === Banana powder has been found to be a "major source of carbohydrate and calories". While it is generally low as a source of protein, the beneficial ingredients of the powder are still "markedly superior to that of other fruits". The powder has also been found to be useful as a general treatment for dyspepsia (indigestion).
Sources: en.wikipedia.org
Dihexa is a synthetic peptide analog of angiotensin IV, often described as an HGF mimetic in research literature. It is studied for effects on synaptic connectivity in laboratory models. It is not an approved medication.
No, dihexa is a synthetic compound derived from the structure of angiotensin IV. Angiotensin IV occurs naturally, but dihexa has modifications that change its properties. It is not a standard dietary component.
The main hypothesis is that dihexa interacts with the hepatocyte growth factor system, possibly through c-Met signaling. This interaction may influence synaptogenesis and neuronal plasticity. The exact molecular target remains an active area of study.
Dihexa is a synthetic peptide investigated in preclinical research. It is often classified as an angiotensin IV analog or an HGF mimetic. It is not an approved medicine.